Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 5/20 | 0.47 |
| ▸ | CNR1 | P21554 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | TSPO | P30536 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17700288 | 0.90 | TSHR (0.54) | TP53CNR2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL28301396 | 0.83 | CYP2C19 (0.61) | TP53CNR2CNR1ALDH1A1LMNA | |
| SCHEMBL8624227 | 0.82 | SMN1; SMN2 (0.57) | TP53ALDH1A1SMN1; SMN2TSHRMAPT | |
| SCHEMBL6778001 | 0.82 | TSPO (0.43) | CNR2ALDH1A1LMNASMN1; SMN2TSHR | |
| SCHEMBL13657714 | 0.81 | ALDH1A1 (0.46) | ALDH1A1LMNATSPOKMT2AMEN1 | |
| SCHEMBL6486856 | 0.81 | NR1H2 (0.52) | CNR2LMNA | |
| SCHEMBL656591 | 0.80 | CNR2 (0.52) | TP53CNR2CNR1SMN1; SMN2TSHR | |
| SCHEMBL8089314 | 0.79 | SMN1; SMN2 (0.58) | TP53ALDH1A1SMN1; SMN2TSHRMAPT | |
| SCHEMBL12762278 | 0.79 | SMN1; SMN2 (0.54) | ALDH1A1SMN1; SMN2TSHRMAPTKMT2A | |
| SCHEMBL6486619 | 0.79 | SMN1; SMN2 (0.54) | CNR2ALDH1A1SMN1; SMN2TSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900244-B2 | Anilino liver X-receptor modulators | PHARMACIA CORPORATION (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040087632-A1 | Controlling metabolism of lipids, cholesterol | PHARMACIA CORPORATION | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087632-A1 | Controlling metabolism of lipids, cholesterol | NR1H2, NR1H3, SREBF1 | TP53 4815/4885CNR2 885/4885CNR1 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.